HispanicBusiness

St. David's, Bermuda--(HISPANIC PR WIRE – PR NEWSWIRE)--January 28, 2008--Warner Chilcott Limited (Nasdaq: WCRX) announced today a view of anticipated full year 2008 results.

Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, and TACLONEX. Gross profit margin, as a percentage of total revenues, is anticipated to be in the range of 80% to 81% in 2008.

Total selling, general and administrative (SG&A) expenses in 2008 are anticipated to be in the range of $228 to $237 million, which reflects the previously disclosed reduction of advertising and promotional spend due to a reduction in DTC advertising in 2008 as compared to 2007. For a detailed view of the components of SG&A please refer to the summary at the end of this press release.

Total R&D spend in 2008 is anticipated to be in the range of $57 to $60 million. Included in this amount is internal R&D expense of $54 to $57 million and anticipated potential milestone payments to third parties of $3 million.

Based on the 2008 view, GAAP net income is expected to be in the range of $118 to $128 million. Cash net income in 2008 is anticipated to be $315 to $325 million. Using 251.0 million Class A shares, the Company expects cash net income per share to be in the range of $1.25 to $1.30 for the full year 2008.

References in this press release to "cash net income" mean the Company's net income adjusted for the after-tax effects of two non-cash items: amortization of intangible assets and amortization (or write-off) of deferred loan costs related to the Company's debt. Reconciliations from the Company's anticipated US GAAP results to cash net income expected results are presented in the footnotes at the end of this press release.

For a full view of the Company's 2008 financial guidance please refer to the summary at the end of this press release.

Conference Call and Audio Webcast Today

Warner Chilcott will be hosting a conference call and audio webcast on January 28, 2008 at 8:30 a.m. to discuss the 2008 Financial Guidance for all interested parties. You may access the conference call by dialing (877) 874-1586 within the US and Canada, and (719) 325-4808 if you are outside the US and Canada. In addition, a live audio webcast of the call will be available at Warner Chilcott's Investor Relations website at http://ir.wcrx.com/events.cfm.

A replay of the conference call will be available for two weeks and can be accessed by dialing (888) 203-1112 from within the US or Canada and (719) 457-0820 if you are located outside the US or Canada. The pass code for the replay is 4419703. An archived version of the webcast will be available for two weeks on the Company's website at the same address noted above.

The Company

Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the United States. WCRX-F

Forward Looking Statements

This press release contains forward-looking statements, including statements concerning the Company's operations, economic performance and financial condition, and business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward- looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.